awmsg logo



eculizumab (Soliris®)


Reference No. 2909

Publication date:
13/12/2019


Appraisal information

eculizumab (Soliris®) 300 mg concentrate for solution for infusion


Company: Alexion Pharma UK Ltd
BNF category: Eye
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 12/12/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, eculizumab (Soliris®) cannot be endorsed for use within NHS Wales in adults for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease
Statement of Advice (SOA)
Download